Next-generation liquid biopsy company, Exai Bio, presented data from its scientific research program on the discovery and validation of tumor-specific, orphan non-coding RNAs (oncRNAs), and the validation of artificial intelligence (AI) profiling of oncRNAs to accurately detect cancers of diverse tissue origins. With these capabilities, Exai Bio, which is founded on UCSF research conducted by Hani Goodarzi PhD, is positioned to develop blood tests for early detection and monitoring of residual disease of many commonly seen cancers.
